P/E ratio for Dr. Reddy's Laboratories (RDY)
P/E ratio as of July 2025 (TTM): 23.6
According to Dr. Reddy's Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.5993. At the end of 2023 the company had a P/E ratio of 23.7.
P/E ratio history for Dr. Reddy's Laboratories from 2002 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | 23.7 | 23.99% |
| 2022 | 19.1 | -32.99% |
| 2021 | 28.5 | -31.56% |
| 2020 | 41.6 | 44.07% |
| 2019 | 28.9 | 16.32% |
| 2018 | 24.8 | -38.86% |
| 2017 | 40.6 | -22.83% |
| 2016 | 52.6 | 152.74% |
| 2015 | 20.8 | -13.79% |
| 2014 | 24.2 | 30.33% |
| 2013 | 18.5 | -10.04% |
| 2012 | 20.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 17.5 | -25.89% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -14.5 | -161.37% | 🇮🇱 Israel |
 GlaxoSmithKline GSK | 24.0 | 1.74% | 🇬🇧 UK |
 Novartis NVS | 18.1 | -23.44% | 🇨🇭 Switzerland |
 Sanofi SNY | 17.4 | -26.36% | 🇫🇷 France |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.